POMDOCTOR Ltd (POM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNYTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 215 | 245 | 305 | 343 | 400 | - | - |
| Operating profit | CNY m | -116 | - | ||||||
| Net profit | CNY m | - | -188 | -126 | -145 | -143 | -213 | - | - |
| EPS reported | CNY | -3.66 | - | ||||||
| Operating cashflow per share | CNY | -2.56 | - | ||||||
| Capex per share | CNY | 0.02 | - | ||||||
| FCF per share | CNY | -2.57 | - | ||||||
| Free cash flow | CNY m | -149 | - | ||||||
| Net debt | CNY m | 443 | - | ||||||
| Book value equity | CNY m | -454 | - | ||||||
| Book value per share | CNY | -8.29 | - | ||||||
| Number of shares | m | 58.08 | - | ||||||
| DPS (TTM paid) | CNY | 0.00 | - |
Financial summary
Financials in CNYTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -4.75 | - | ||||||
| P/S LTM | x | 5.39 | - | ||||||
| P/FCF LTM | x | -14.43 | - | ||||||
| EV/EBITDA LTM | x | -22.07 | - | ||||||
| EV/Sales LTM | x | 6.51 | - | ||||||
| Earnings Yield LTM | % | -9.86% | - | ||||||
| FCF Yield | % | -6.93% | - | ||||||
| Quality | |||||||||
| ROE | % | +46.83% | - | ||||||
| ROIC | % | +4.42% | - | ||||||
| Operating margin | % | -29.10% | - | ||||||
| Gross margin | % | +13.07% | - | ||||||
| FCF/Sales | % | -37.38% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +16.74% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -0.33 | - | ||||||
| Net Debt/EBITDA | x | -3.78 | - | ||||||
| EBIT/Net interest | x | -9.03 | - | ||||||
| Net debt/market cap | % | +20.96% | - | ||||||
| Net debt/Equity | x | -0.97 | - | ||||||
| Gross debt/equity | x | -1.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free